bendamustine

P2, N=43, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P=N/A, N=222, Completed, University Hospital, Bordeaux | Not yet recruiting --> Completed | Initiation date: Sep 2025 --> Feb 2025

As a further biopsy would have required general anesthesia and might still have yielded insufficient tissue for definitive subclassification, treatment was initiated for an unclassifiable low-grade B-cell lymphoma, with a plan to perform a repeat biopsy at recurrence for diagnostic confirmation. The patient subsequently received chemotherapy with bendamustine and rituximab and has sustained a complete response for seven years.

P3, N=250, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

P1/2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center

P2, N=135, Completed, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Sep 2025 | Active, not recruiting --> Completed

Within the limitations of the size of our study and its retrospective nature, flu/cy and bendamustine LD resulted in similar ORR, PFS and OS; however, bendamustine had less hematologic toxicity. Bendamustine can be a viable alternative LD agent for CART-19 therapy for DLBCL, especially in patients with a compromised performance status.

P2, N=60, Recruiting, Christine Ryan | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Apr 2025

Treatment with intravenous rituximab was initiated, followed by bendamustine/rituximab (BR) therapy protocol as first-line treatment. This case highlights the importance of recognising the coexistence of CAD and WM, which may present with overlapping clinical features, including life-threatening anaemia. Extensive diagnostics and prompt treatment with combination therapy can lead to effective clinical improvement.

Over subsequent years, she experienced multiple relapses, treated with bendamustine-rituximab and later lenalidomide, achieving remission...She received high-dose methotrexate, rituximab, and temozolomide with Stereotactic Body Radiotherapy (SBRT) for melanoma. Despite significant intracranial progression, she remained largely asymptomatic and prioritized quality of life, highlighting the challenges of individualized care in complex dual malignancies.

Before transformation, three patients were treated with Bruton tyrosine kinase inhibitor therapy, and one patient was treated with the bendamustine plus rituximab regimen...Posttransformation, the patients were mainly treated with the rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (R-CHOP) regimen, with an optimal outcome of partial remission...Patients should remain highly vigilant for transformation if they develop rapidly enlarging lymph nodes and/or newly involved lymph nodes, worsening systemic symptoms, and declining body mass. R-CHOP regimen may induce a partial response in some cases; however, the overall prognosis remains poor.

Pretreatment with an antibody blocking OX40-OX40L signaling attenuated bendamustine-induced T-cell depletion in mice, whereas preserving the cytotoxic effect of bendamustine on transplanted B-cell lymphoma. In conclusion, both the antilymphoma effect and the T-lymphopenia induced by bendamustine are associated with TNFRSF signaling, and the T-cell toxicity can be separately controlled by blocking OX40 signaling before bendamustine administration.